Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe-Reference-Cited by-同舟云学术

Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe

Published:2024-09 Issue:9 Volume:30 Page:1197.e1-1197.e4
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Günther Gunar,Guglielmetti Lorenzo,Kherabi Yousra,Duarte Raquel,Lange Christoph

Funder

DZIF

Publisher

Elsevier BV

Reference11 articles.

1. Global tuberculosis report 2023,2023

2. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis;Conradie;N Engl J Med,2022

3. A 24- week, all-oral regimen for rifampin-resistant tuberculosis;Nyang'wa;N Engl J Med,2022

4. WHO consolidated guidelines on tuberculosis. Module 4: treatment drug-resistant tuberculosis treatment, 2022 update,2022

5. Availability and costs of medicines for the treatment of tuberculosis in Europe;Gu¨nther;Clin Microbiol Infect,2023

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response;Clinical Microbiology and Infection;2024-09

2. Re: ‘Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe’ by Lange et al.;Clinical Microbiology and Infection;2024-09

3. Bedaquiline: what might the future hold?;The Lancet Microbe;2024-07

4. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023;Eurosurveillance;2024-04-25

5. Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland;Respiration;2024